Press

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Aug 21 • 3 min read

Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773. In connection with this issuance, the Company also issued 17,691 common shares…

Novel Combination of Oral Ketamine and Aspirin Is Safe Form of Pain Medication after Total Knee Replacement Surgery

Aug 17 • 4 min read

In response to the opioid crisis, researchers at Hospital for Special Surgery (HSS) are looking for alternate ways to reduce pain after orthopedic procedures. In an innovative pilot study that was recently completed, investigators led by Michael P. Ast, MD, hip and knee surgeon and Chief Medical Innovation Officer at HSS, showed that a combination of…

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

Aug 17 • 5 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 American Depositary Shares (“ADSs”) representing 16,076,750 ordinary shares, and (ii)…

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Aug 15 • 5 min read

Mydecine Innovations Group (OTC: MYCOF / FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six months ended June 30, 2023. Financial Results for the Six Months Ended June 30,…

Filament Health and Nasdq-Listed SPAC Jupiter Acquisition Corp. Announce Filing of SEC Registration Statement

Aug 15 • 5 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”), a special purpose acquisition company (“SPAC”), today announced the filing of a registration statement by 1427702 B.C. Ltd. (“TopCo”) on Form F-4 (the “Registration Statement”), which contains a preliminary proxy statement/prospectus, with the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441